Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma

  title={Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma},
  author={Daniel Roncone and Anjali A. Satoskar and Tibor Nadasdy and J. Paul Monk and Brad H. Rovin},
  journal={Nature Clinical Practice Nephrology},
Background A 59-year-old man who had undergone a left nephrectomy for renal cell carcinoma was found to have metastatic disease during a restaging examination. The patient was started on treatment with interferon α2b plus bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor antibody. After 9 months of this therapy, the patient developed proteinuria, which gradually increased to over 6 g/day.Investigations Physical examination, urine and blood analysis, biopsy of the right… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 41 extracted citations


Publications referenced by this paper.
Showing 1-10 of 18 references

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

  • BF Schrijvers
  • Kidney Int
  • 2004

Vascular endothelial growth factor-165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis

  • A Shimizu
  • J Am Soc Nephrol
  • 2004

Similar Papers

Loading similar papers…